Olympus Medical Systems: Unreported Infections and the Duodenoscope Pleas

In the Olympus Medical Systems adverse event reporting guilty plea, the Tokyo manufacturer admitted failing to submit required infection reports while continuing to sell duodenoscopes in the United States. An outside expert had identified places in the device’s tip where bacteria could hide and cleaning was difficult. The company’s top regulatory official knew about the obligation to send additional information to the Food and Drug Administration and admitted his part in the failure. For a quality or regulatory employee, the central question is familiar: what happened between receiving the warning and deciding what the regulator would see?

Olympus Medical Systems Corporation pleaded guilty on December 10, 2018, in federal court in Newark, New Jersey. Its admissions concerned the TJF-Q180V duodenoscope and three separate infection events in Europe. Two required updates to reports already filed. The third required an initial report that Olympus had failed to submit.

What Olympus Admitted About the Three Infection Events

In its guilty plea, Olympus admitted failing to file required adverse event reports concerning infections in the Netherlands and France. Olympus had already told the Food and Drug Administration about some of these infections. The failure included keeping required follow-up information out of the reporting system.

At Erasmus Medical Center in the Netherlands, approximately 22 patients contracted Pseudomonas aeruginosa infections in early 2012. Olympus filed an initial Medical Device Report about that event but failed to file a required supplemental report. The outside expert’s investigation of the scope became part of that missing follow-up.

At Clinique de Bercy in France, three patients contracted Escherichia coli infections in November 2012. Olympus had also filed an initial report for that event. It admitted failing to submit the required supplemental information.

At Kremlin Bicetre in France, five patients contracted Pseudomonas aeruginosa infections in July 2012. Here, Olympus admitted failing to make the initial report at all.

In its guilty plea, Olympus admitted three counts of distributing scopes after these reporting failures. For someone reviewing the internal complaint files, each event presents a different comparison: what the company first learned, what it initially reported, and what it learned afterward. An initial report can sit in the file while the most useful later information stays inside the business.

The Expert Report Reached Olympus

The Erasmus event brought Olympus information about the device itself. According to the Justice Department’s account of the criminal admissions, the company received a report from an independent expert at Delft University of Technology in the summer of 2012. The expert identified cracks, corners and crevices in the Q180V’s tip that could harbor bacteria and were difficult to clean.

The recommendations were concrete: immediately investigate all such scopes, update the cleaning instructions, and improve the quality of the seals. Those recommendations reached beyond the history of an individual patient’s infection. They concerned the design and cleaning of the product Olympus was selling.

That is why the supplemental report mattered. The Food and Drug Administration requires manufacturers to submit additional information about a reported event when they later obtain information that was unknown or unavailable at the time of the initial filing. The expert’s findings belonged in the continuing account of the Erasmus infections. Olympus admitted that the required follow-up did not reach the agency.

The expert linked the concern to the scope’s tip, cleaning instructions and seals. A reporting review that stops at the original infection complaint misses the information the investigation added.

The Regulatory Official Who Knew About the Follow-Up Duty

Olympus’s top regulatory official admitted personal responsibility for the Erasmus reporting failure. In his one-count guilty plea in December 2018, the official admitted that he knew about the supplemental-reporting obligation and was involved in the failure to submit the required report concerning the infections and the outside expert’s findings.

His role was division manager for the Quality and Environment Division, with responsibility for adverse event reporting in the United States. His admission concerned the Erasmus event, while the company’s plea covered all three infection events.

That puts a specific decision inside a specific function. The information had reached the manufacturer, and the person responsible for U.S. reporting knew about the duty to supplement. An employee who saw that review would have a view of the case that an infection count alone could never provide.

Why European Infections Mattered to U.S. Sales

The U.S. case concerned Olympus’s continued distribution of duodenoscopes after it failed to make the required reports. The infections occurred in Europe, but the reporting obligation followed the device into the American market.

The Justice Department explained the connection in its account of the guilty plea. Under the Federal Food, Drug, and Cosmetic Act, Olympus could not lawfully ship scopes across state lines while their required reports remained unfiled. Between August 2012 and October 2014, Olympus shipped hundreds of those duodenoscopes in the United States, generating approximately $40 million in revenue while required safety reports went unfiled.

The Justice Department said the reporting failures put patients’ health at risk. The people handling orders could see the commercial activity. People in quality and regulatory affairs could see the expert report and the reporting decisions. Connecting those parts of the business explains how a warning about infections in Europe became a case about devices sold in the United States.

The Manufacturer Controls a Crucial Part of the Reporting Trail

Olympus admitted that it failed to submit the required supplemental report concerning the Erasmus infections and the outside expert’s findings. Comparing the hospital’s original report, the expert’s later findings and the company’s submission to the Food and Drug Administration shows where the information stopped moving.

The Separate Olympus Kickback Case

Olympus Corporation of the Americas agreed to a $310.8 million civil False Claims Act settlement in March 2016 over allegations that payments to doctors and hospitals induced equipment purchases. That civil kickback settlement involved a different Olympus company and purchasing conduct, while Olympus Medical Systems’ later reporting plea concerned safety information withheld from FDA.

What Evidence Is Needed to Prove Fraud?

For a device-reporting concern, we examine the connection between what the manufacturer knew, what it told the Food and Drug Administration and healthcare providers, and the government-paid care involving the product. Our whistleblower experts work with you to determine how your view inside the company fits that chain.

Olympus supplies a concrete starting point: an initial report, an expert’s findings that arrived later, a regulatory official’s admitted knowledge, and continued U.S. sales. The internal event file can show what reached the reporting team. The technical report can show what changed the company’s understanding. The submission history can show what the agency received.

We work with you and medical device whistleblower lawyers to assess whether the withheld safety information affected government-paid care and the bills submitted for it. A person in quality, regulatory affairs, engineering or compliance may hold a decisive part of the account without seeing the entire payment history.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Saw Where the Warning Stopped

If you saw an infection report, technical finding or safety warning kept out of a required submission, tell our whistleblower experts what happened inside the company. We work beside you to build the strongest case your knowledge supports and bring in medical device whistleblower lawyers who understand safety reporting and government payment. Your account of the reporting decision is where that work begins.